Press releases

11/09/2024
PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 productionPanTera today announces that it has completed a EUR 93 million oversubscribed Series A fundraise led by EQT Life Sciences, with additional equity and debt funding bringing the total amount raised to EUR 134 million. Sven Van den Berghe, CEO of PanTera, said: “With this funding, we are now en route to realise our vision of providing a “Better Fight for Life” to cancer patients worldwide by becoming a dependable global 225Ac supplier.” Read More to see our full Press Release.Read more
Radioisotope production facility with Tractebel, MODULO and PanTera
28/03/2024
Tractebel and Modulo architects strengthen their partnership with PanTera to design a medical radioisotope production facilityJointly with its partner Modulo architects, Tractebel will combine its infrastructure and nuclear expertise to support the design and construction of PanTera's actinium-225 production facility in Belgium, enabling breakthrough cancer treatment production Read more
PanTera signs a second agreement for the supply of actinium-225PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac22514/03/2024Read more
PanTera signs agreement with Bayer for the supply of actinium-225Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients.13/02/2024Read more
PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer26/06/2023Read more
IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV22/09/2022Read more